Abstract. It has been previously reported that the long non-coding RNA nuclear enriched abundant transcript 1 (NEAT1) can regulate cell apoptosis. The present study aimed to investigate the involvement of NEAT1 in premature ovarian failure (POF). A total of 60 patients with POF admitted at the Sixth Affiliated Hospital of Sun Yat-sen University between December 2016 and December 2018 were enrolled in the present study. Reverse transcription-quantitative PCR (RT-qPCR) was performed to measure NEAT1 expression level in tissue samples from patients with POF and healthy controls. Transient transfections were performed on two normal Chinese hamster ovary cell lines Lec8 and CHO, followed by RT-qPCR and western blot to evaluate gene interaction. Flow cytometry was performed to assess cell apoptosis. The results from the present study demonstrated that NEAT1 expression in ovarian tissues was significantly downregulated in patients with POF compared with healthy controls. Furthermore, the expression of p53 was upregulated in ovarian tissues from patients with POF compared with healthy controls and was inversely associated with NEAT1 expression. In hamster ovary cells, overexpression of NEAT1 led to inhibition of p53, whereas NEAT1 knockdown promoted the expression of p53. In addition, ovary cell apoptosis was inhibited following NEAT1 overexpression and stimulated following p53 overexpression. In conclusion, overexpression of NEAT1 may inhibit the expression of p53 and improve premature ovarian failure.

Introduction

Premature ovarian failure (POF), also known as primary ovarian insufficiency, is a hypergonadotropic disorder characterized by the exhaustion of ovary reserve before the age of 40 years (1). Patients with POF suffer from amenorrhea or oligomenorrhea, low estrogen level, high follicle-stimulating hormone (FSH) level, infertility and clinical manifestations associated with perimenopause (2). In clinical practice, POF is diagnosed by the elevated serum level of FSH and amenorrhea (≥4 months) (3). POF is one of the major causes of female infertility and affects 1/1,000 infertile females worldwide (4). In China, ~3% of females of childbearing age will develop POF and subsequent infertility before the age of 40 years (5). POF causes economic burden and mental stress to the patients' families (5).

Despite the efforts made in POF treatment, such as estrogen therapy, infertility remains difficult to treat, especially in patients diagnosed with severe forms of the disease (6-8). Genetic mutations, such as PTEN mutations, are frequently observed in POF patients and play central roles in the occurrence and development of this disease (9,10). Apart from protein-coding genes, non-coding RNAs (ncRNAs), including long ncRNAs [lncRNAs (>200 nucleotides in length)] also serve crucial roles in diverse biological processes, including the development of POF, such as cell proliferation and apoptosis (11,12). However, the function of most lncRNAs in POF is still unknown (11,12). The lncRNA nuclear enriched abundant transcript 1 (NEAT1) is involved in different types of cancer, including ovarian and oral cancer, and regulates cancer cell behaviors, for example through inhibition of cell apoptosis (13,14). A previous study reported that NEAT1 could inhibit hydrogen peroxide induced cardiomyocyte apoptosis (15). Cell apoptosis is known to promote the progression of POF (4,9,10). Preliminary RNA-seq analysis from our laboratory suggested altered expression of NEAT1 in POF (data not shown). The present study therefore hypothesized that NEAT1 may also participate in POF. The present study aimed to determine the role of NEAT1 in POF.

Materials and methods

Subjects. A total of 60 patients with spontaneous (not induced by chemotherapy, radiation or surgery) POF (age range,
21-39 years; mean age, 28.1±4.6 years) that were admitted at The Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China) between December 2016 and December 2018 were enrolled in the present study. All patients were diagnosed with POF based on their FSH level. Patients with FSH level ≥30 IU/l (measured twice at 4 weeks interval) were included in the study. Patients with POF who had other clinical complications, including other types of ovarian disorders, such as endometriosis, ovarian cysts and ovarian cancers, were excluded from this study. No therapy was initiated prior to admission. The control group consisted of 60 healthy women (age range, 21-39 years; mean age, 28.2±4.4 years) who were also enrolled at the aforementioned hospital between December 2016 and December 2018. These healthy women had suspected ovarian lesions that were removed during ovarian biopsy. All participants provided their written informed consent and the study was approved by the Ethics Committee of The Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China).

Tissues, cell lines and culturing. Ovarian biopsy was performed on ovaries of all patients and healthy women to collect ovarian tissue samples (0.08-0.12 g) from each participant. The two normal Chinese hamster ovary cell lines Lec8 and CHO (American Type Culture Collection) were used in the present study. Cells were cultured in ovarian epithelial cell medium (OEpiCM; ScienCell Research Laboratories, Inc.) supplemented with antibiotic-antimycotic (10,000 U/ml penicillin, 10,000 µg/ml streptomycin and 25 µg/ml amphotericin B from Thermo Fisher Scientific, Inc.) at the following thermal conditions: 55˚C for 20 min and 80˚C for 20 min. KAPA SYBR FAST qPCR Master Mix (Kapa Biosystems; Roche Diagnostics) was used to prepare all qPCR mixtures. 18S rRNA qPCR Master Mix (Kapa Biosystems; Roche Diagnostics) at the following thermal conditions: 95˚C for 1 min, followed by 95˚C for 10 sec and 58˚C for 50 sec. The 2^ΔΔCq method (16) was used to normalize data. Three replicates were conducted for each experiment. Primer sequences were: 5'-CTTCCTCCCTTTAACTTTACATTACCTAC-3' (forward) and 5'-CTCTTCTCCACCATTACCAAAATAC-3' (reverse) for NEAT1; 5'-AGAGTTCTATAGGGCCACCCTC-3' (forward) and 5'-GCTCGACCGTAGGTCTGAC-3' (reverse) for p53; 5'-GTTCTCCCTGACTTCAACAGCG-3' (forward) and 5'-ACCACCTCTTGTCTTAGCCCA-3' (reverse) for GAPDH; 5'-CTACCACTCCAAGGAAGCA-3' (forward) and 5'-TTTTTGCTGACTACCTCCCG-3' (reverse) for 18S rRNA.

Western blotting. Lec8 and CHO cells (10⁶ cells) collected 24 h after transfection were mixed with 0.1 ml ice-cold RIPA buffer (Sangon Biotech Co., Ltd.) for total protein extraction. BCA assay (Invitrogen; Thermo Fisher Scientific, Inc.) was used to determine protein concentration. Proteins (40 µg) were separated by 10% SDS-PAGE and transferred onto PVDF membranes. Membranes were blocked using 5% non-fat milk at room temperature for 2 h. Membranes were incubated with primary antibodies against GAPDH (1:1,500; cat. no. ab9485; Abcam) and p53 (1:1,500; cat. no. ab31333; Abcam) at 4˚C overnight. Subsequently, the membranes were incubated with IgG-horseradish peroxidase secondary antibody (1:1,000; goat anti rabbit; cat. no. MBS435036; MyBioSource, Inc.) at room temperature for 2 h. Bands were detected using enhanced chemiluminescence substrate (Merck KGaA).

Reverse transcription-quantitative (RT-q) PCR. Total RNA was extracted from ovarian tissues (0.05 g) or Lec8 and CHO cells (10⁶) using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific Inc.). Following DNase I digestion, cDNA was synthesized using a QuantiTect reverse transcription kit (Qiagen China Co., Ltd.) at the following thermal conditions: 55˚C for 20 min and 80˚C for 20 min. KAPA SYBR FAST qPCR Master Mix (Kapa Biosystems; Roche Diagnostics Co., Ltd.) was used to prepare all qPCR mixtures. 18S rRNA or GAPDH were used as endogenous controls to detect the expression of NEAT1 and p53 mRNA, respectively. PCR reaction conditions were: 95˚C for 1 min, followed by 95˚C for 10 sec and 58˚C for 50 sec. Relative expression was calculated using the 2^ΔΔCq method (16) with GAPDH or 18S rRNA as an endogenous control. Data were analyzed using GraphPad Prism software (version 6.0; GraphPad Software, Inc.).

Figure 1. Expression of NEAT1 was reduced in ovarian tissue from patients with POF. RNA expression of NEAT1 was detected using reverse transcription-quantitative PCR and expression data were compared between POF and control groups using unpaired t-test. *P<0.05. NEAT 1, nuclear enriched abundant transcript 1; POF, premature ovarian failure.
expression level was normalized to endogenous control GAPDH using ImageJ version 1.46 (National Institutes of Health).

**Statistical analyses.** Data are presented as the mean ± SD values of three independent experiments. Unpaired t-test was used to compare differences between two groups. ANOVA followed by the Tukey’s post hoc test was used for multiple comparison. Associations were analyzed using linear regression. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**NEAT1 expression is downregulated in ovarian tissues of patients with POF.** NEAT1 expression in ovarian tissues of patients from both the POF and control groups was detected using RT-qPCR. The results demonstrated that expression level of NEAT1 was significantly decreased in patients with POF compared with healthy controls (Fig. 1).

**p53 mRNA expression is inversely associated with NEAT1 expression in patients with POF.** RT-qPCR was used to detect the expression level of p53 in ovarian tissues of patients from both the POF and control groups. The mRNA expression level of p53 was significantly increased in the POF group compared with the control group (Fig. 2A). Furthermore, association between p53 mRNA and NEAT1 expression was analyzed using linear regression. The results demonstrated that p53 and NEAT1 expression levels were inversely associated in the POF group (Fig. 2B). However, p53 and NEAT1 expression levels were not associated in the control group (Fig. 2C).

**NEAT1 negatively regulates p53 in Lec8 and CHO cells.** NEAT1 expression vector and siRNA were transfected into Lec8 and CHO cells. At 24 h following transfection, expression of NEAT1 was significantly altered in both cell lines compared with the C and NC groups (Fig. 3A). Furthermore, cells overexpressing NEAT1 demonstrated significantly downregulated mRNA and protein levels of p53 (Fig. 3B). Cells that had NEAT 1 silenced demonstrated significantly upregulated mRNA and protein levels of p53 (Fig. 3C).

**NEAT1 inhibits Lec8 and CHO cell apoptosis through p53.** Overexpression of p53 was also achieved 24 h following transfection (Fig. S1). Compared with the C and NC controls, overexpression of NEAT1 inhibited Lec8 (Fig. 4A) and CHO (Fig. 4B) cell apoptosis. Overexpression of p53 promoted Lec8 and CHO cell apoptosis. In addition, overexpression of p53 attenuated the effects of overexpressing NEAT1 on cell apoptosis.

**Discussion**

NEAT1 expression pattern and its role in POF was investigated in the present study. The results demonstrated that NEAT1 was downregulated in ovarian tissues from patients with POF, and that NEAT1 downregulated p53 and subsequently ovarian cell apoptosis.

Cell apoptosis in ovarian tissues promotes POF (17). As a key player in the regulation of cell apoptosis, p53 has been implicated in POF (18,19). In a rat model of POF, Liu et al (18) demonstrated the activation of p53. Another study also observed upregulated p53 in the female rat POF model (20). The present study demonstrated that p53 expression was upregulated in ovarian tissues...
LI et al: NEAT1 OVEREXPRESSION INHIBITS p53 EXPRESSION AND IMPROVES POF

Figure 3. NEAT1 negatively regulated p53 in Lec8 and CHO cells. NEAT1 expression vector and siRNA were transfected into Lec8 and CHO cells and overexpression was confirmed 24 h later. (A) The effects of NEAT1 overexpression (B) and knockdown (C) on the expression of p53 were analyzed by RT-qPCR. *P<0.05. NEAT 1, nuclear enriched abundant transcript 1; POF, premature ovarian failure; C, untransfected cells; NC, negative control (empty pcDNA3 vector); siRNA, small interfering RNA (NEAT 1siRNA).

from patients with POF compared with healthy women. In addition, increased apoptotic rates of two normal ovary cell lines were observed following p53 overexpression. The present study further indicated the involvement of p53 in POF.
NEAT1 has been indicated to be a transcriptional target of p53 (21). Although previous studies have characterized the functionality of multiple lncRNAs in POF, the interaction between lncRNAs and p53 in POF remains unclear (18,19). In the present study, an inverse association between NEAT1 and p53 expression was found in patients with POF. In addition, NEAT1 negatively regulated the expression of p53 in normal ovary cells. This observation is possibly due to disease specific patterns of p53 expression. p53 has been suggested to be downregulated in ovarian cancer and to suppress cell apoptosis but is suggested to be upregulated in POF to induce cell apoptosis (18,19,21). NEAT1 may serve as a microRNA
sponge in pathological processes, such as the apoptosis of cardiomyocytes (15). Future work may explore the possible involvement of additional miRNAs in mediating the regulation of p53 expression by NEAT1.

It has been reported that NEAT1 can inhibit cancer cell proliferation and promote cancer cell apoptosis in ovarian cancer (13). However, in the present study, NEAT1 inhibited apoptosis of normal ovarian cell apoptosis following NEAT1 overexpression. NEAT1 may therefore serve opposing roles in different types of disease originating from the same site.

This study is limited by the lack of in vivo animal model experiments. We will further confirm our conclusions by performing animal model experiments in our future studies.

In conclusion, NEAT1 was downregulated in POF tissues and overexpression of NEAT1 in ovarian cells inhibited cell apoptosis by downregulating p53.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

ML and JP performed the experiments, clinical research, data analysis and wrote the manuscript. ZZ conceived and designed the study, performed literature research and reviewed the manuscript for important intellectual content. All authors have read and approved the manuscript.

Ethics approval and consent to participate

All participants were informed of the experimental details. This study was approved by the Ethics Committee of The Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China; approval no. SAHSYU2016101725655) and all the procedures were performed in accordance with the Declaration of Helsinki. Each patient provided signed informed consent.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Goswami D and Conway GS: Premature ovarian failure. Hum Reprod Update 11: 391-410, 2005.
2. Kovanci E and Schutt AK: Premature ovarian failure: Clinical presentation and treatment. Obstet Gynecol Clin North Am 42: 153-161, 2015.
3. Nelson LM: Clinical practice. Primary ovarian insufficiency. N Engl J Med 360: 606-614, 2009.
4. Liu T, Qin W, Huang Y, Zhao Y and Wang J: Induction of estrogen-sensitive epithelial cells derived from human-induced pluripotent stem cells to repair ovarian function in a chemotherapy-induced mouse model of premature ovarian failure. DNA Cell Biol 32: 685-698, 2013.
5. Wu X, Cai H, Kallianpur A, Li H, Yang G, Gao J, Xiang YB, Ji BT, Tang Y, Zheng W and Shu XO: Impact of premature ovarian failure on mortality and morbidity among Chinese women. PLoS One 9: e89597, 2014.
6. Kawamura K, Kawamura N and Hsueh AJ: Activation of dormant follicles: A new treatment for premature ovarian failure? Curr Opin Obstet Gynecol 28: 217-222, 2016.
7. Jankowska K: Premature ovarian failure. Prz Menopauzalny 16: 51-56, 2017.
8. Chen Y, Tang H, Wang L, He J, Guo Y, Liu Y, Liu X and Lin H: Fertility enhancement but premature ovarian failure in esr1-deficient female zebrafish. Front Endocrinol (Lausanne) 9: 567, 2018.
9. Chapman C, Cree L and Shellng AN: The genetics of premature ovarian failure: Current perspectives. Int J Womens Health 7: 799-810, 2015.
10. Bilgin EM and Kovanci E: Genetics of premature ovarian failure. Curr Opin Obstet Gynecol 27: 167-174, 2015.
11. Engreitz JM, Ollikainen N and Guttman M: Long non-coding RNAs: Spatial amplifiers that control nuclear structure and gene expression. Nat Rev Mol Cell Biol 17: 756-770, 2016.
12. Zhao W and Dong L: Long non-coding RNA HOTAIR overexpression improves premature ovarian failure by upregulating Notch-1 expression. Exp Ther Med 16: 4791-4795, 2018.
13. Ding N, Wu H, Tao T and Peng E: NEAT1 regulates cell proliferation and apoptosis of ovarian cancer by miR-34a-5p/BCL2. Onco Targets Ther 10: 4905-4915, 2017.
14. Liu X, Shang W and Zheng F: Long non-coding RNA NEAT1 promotes migration and invasion of oral squamous cell carcinoma cells by sponging microRNA-365. Exp Ther Med 16: 2243-2250, 2018.
15. Hong Y, Huasheng L, Lie L, Dongli C and Qianhua Z: Long noncoding RNA NEAT1 sponges miR125a5p to suppress cardiomyocyte apoptosis via BCL2L12. Mol Med Rep 19: 4468-4474, 2019.
16. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
17. Chen W, Xu X, Wang L, Bari G and Xiang W: Low expression of Mfn2 Is associated with mitochondrial damage and apoptosis of ovarian tissues in the premature ovarian failure model. PLoS One 10: e0136421, 2015.
18. Liu TE, Zhang L, Wang S, Chen C and Zheng J: Tripterygium glycosides induce premature ovarian failure in rats by promoting p53 phosphorylation and activating the serine/threonine kinase 11-p53-p21 signaling pathway. Exp Ther Med 10: 12-18, 2015.
19. Levine AJ, Tomasiini R, McKeon FD, Mak TW and Melino G: The p53 family: Guardians of maternal reproduction. Nat Rev Mol Cell Biol 12: 259-265, 2011.
20. Liu Y, Li YJ, Wang N, Liu Z, Yang H, Liu Y and Wang F: The expression changes of p53 and p21 in female rats of premature ovarian failure in fluorosis. Chongqing Medicine 47: 1712-1715, 2018.
21. Idogawa M, Ohashi T, Sasaki Y, Nakase H and Tokino T: Long non-coding RNA NEAT1 is a transcriptional target of p53 and modulates p53-induced transactivation and tumor-suppressor function. Int J Cancer 140: 2785-2791, 2017.